Literature DB >> 7745743

Isolation of Epstein-Barr virus-infected clones of the human T-cell line MT-2: use of recombinant viruses with a positive selection marker.

S Fujiwara1, Y Ono.   

Abstract

Certain classes of human T-cell lymphomas have been shown to be persistently infected with Epstein-Barr virus (EBV). To achieve an experimental system of persistent EBV infection in T cells, we used EBV recombinants with a positive selection marker. Infection of the human T-cell line MT-2 with EBV recombinants that had a hygromycin resistance gene and subsequent selection with this drug permitted isolation and long-term maintenance of EBV-infected MT-2 clones. For each clone, essentially 100% of cells were positive for EBV nuclear antigen. These MT-2 clones harbor monoclonal episomes of EBV DNA and stably express two EBV latent proteins, EBV nuclear antigen 1 and latent membrane protein 1. The growth of these EBV-infected MT-2 clones was slower than that of uninfected clones, suggesting that EBV affects regulation of T-cell proliferation. EBV recombinants with a positive selection marker will be a useful tool in establishing experimental systems of persistent EBV infection in certain non-B-cell lineages.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745743      PMCID: PMC189114          DOI: 10.1128/JVI.69.6.3900-3903.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.

Authors:  D Wang; D Liebowitz; F Wang; C Gregory; A Rickinson; R Larson; T Springer; E Kieff
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

2.  Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells.

Authors:  K P Mann; D Staunton; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

3.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

4.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

5.  The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation.

Authors:  N Raab-Traub; K Flynn
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

6.  Epstein-Barr virus in adult T-cell leukemia/lymphoma.

Authors:  M Tokunaga; S Imai; Y Uemura; T Tokudome; T Osato; E Sato
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

7.  Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man.

Authors:  G Milman; A L Scott; M S Cho; S C Hartman; D K Ades; G S Hayward; P F Ki; J T August; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

8.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.

Authors:  J F Jones; S Shurin; C Abramowsky; R R Tubbs; C G Sciotto; R Wahl; J Sands; D Gottman; B Z Katz; J Sklar
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

9.  Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease.

Authors:  H Kikuta; Y Taguchi; K Tomizawa; K Kojima; N Kawamura; A Ishizaka; Y Sakiyama; S Matsumoto; S Imai; T Kinoshita
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962

10.  Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.

Authors:  Y Hinuma; K Nagata; M Hanaoka; M Nakai; T Matsumoto; K I Kinoshita; S Shirakawa; I Miyoshi
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

View more
  5 in total

1.  Epstein-barr virus (EBV) nuclear protein 2-induced disruption of EBV latency in the Burkitt's lymphoma cell line Akata: analysis by tetracycline-regulated expression.

Authors:  S Fujiwara; Y Nitadori; H Nakamura; T Nagaishi; Y Ono
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program.

Authors:  Rosemary Tierney; Jasdeep Nagra; Isabel Hutchings; Claire Shannon-Lowe; Markus Altmann; Wolfgang Hammerschmidt; Alan Rickinson; Andrew Bell
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

3.  Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells.

Authors:  Ken-ichi Imadome; Misako Yajima; Ayako Arai; Atsuko Nakazawa; Fuyuko Kawano; Sayumi Ichikawa; Norio Shimizu; Naoki Yamamoto; Tomohiro Morio; Shouichi Ohga; Hiroyuki Nakamura; Mamoru Ito; Osamu Miura; Jun Komano; Shigeyoshi Fujiwara
Journal:  PLoS Pathog       Date:  2011-10-20       Impact factor: 6.823

4.  Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.

Authors:  Mohammed N A Siddiquey; Hikaru Nakagawa; Seiko Iwata; Tetsuhiro Kanazawa; Michio Suzuki; Ken-Ichi Imadome; Shigeyoshi Fujiwara; Fumi Goshima; Takayuki Murata; Hiroshi Kimura
Journal:  Cancer Sci       Date:  2014-05-13       Impact factor: 6.716

5.  The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.

Authors:  Michio Suzuki; Tadashi Takeda; Hikaru Nakagawa; Seiko Iwata; Takahiro Watanabe; Mohammed N A Siddiquey; Fumi Goshima; Takayuki Murata; Jun-Ichi Kawada; Yoshinori Ito; Seiji Kojima; Hiroshi Kimura
Journal:  Front Microbiol       Date:  2015-04-09       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.